loader from loading.io

In the News... weekly basal + semaglutide, liver targeted insulin, Lance Bass educates about LADA, and more!

Diabetes Connections | Type 1 Diabetes

Release Date: 08/16/2024

In the News... Omnipod 5 iPhone update, Libre & Dexcom news, overnight insulin pump and more! show art In the News... Omnipod 5 iPhone update, Libre & Dexcom news, overnight insulin pump and more!

Diabetes Connections | Type 1 Diabetes

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: iPhone control for Omnipod 5 rolls out, Libre is approved for use in CT scans and MRIs, Dexcom files for 15 day wear, Luna nighttime pump goes to trial, iLet cell trials move forward and more! Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about   from extreme temperatures Learn more about  Drive  The best way to keep up with Stacey and the show is by signing up for our weekly...

info_outline
Lisa Katzenberger on 'It Belongs to the World,' Frederick Banting's Story, and Her Family’s T1D Journey show art Lisa Katzenberger on 'It Belongs to the World,' Frederick Banting's Story, and Her Family’s T1D Journey

Diabetes Connections | Type 1 Diabetes

I talk to a LOT of people who have a child diagnosed with diabetes, so they decide to write a book. I don’t talk to a lot of children’s book authors who decide to write about diabetes. Lisa Katzenberger’s newest book – It Belongs to the World - is out right now and it tells the story of Frederick Banting. We talk about her family’s T1D story, why she wanted to write it, how the illustrator has a type 1 connection, and we get some insight into what it takes to go the traditional publishing route these days. This podcast is not intended as medical advice. If you have those kinds of...

info_outline
Eversense 365: A deep dive into the  CGM system that lasts a year show art Eversense 365: A deep dive into the CGM system that lasts a year

Diabetes Connections | Type 1 Diabetes

Eversense is now a 365 day continuous glucose monitor. Their ads say One Year – One CGM. Eversense is the only CGM with a sensor that sits fully under the skin – the transmitter still sits on top but you can take that on and off. Earlier this year the FDA designated the device an iCGM which means it can now work with insulin pumps. Lots of milestones here and lots of questions for Brian Hanson, President of CGM at Ascensia Diabetes Care, the company behind eversense. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care...

info_outline
Schools are still pushing back on CGM. How you can help the legal fight for change show art Schools are still pushing back on CGM. How you can help the legal fight for change

Diabetes Connections | Type 1 Diabetes

Earlier this year, it looked like a big win for parents of kids with diabetes when the DOJ ruled that CGM can be considered standard of care.  Unfortunately, the lawyers fighting for families in this case tell me it’s not that simple, the Dept of Justice ruling may have to be litigated on the local levels across the country. They’re back to talk to me about what happened, what you need to know, and how you can make your issue known, if your child’s school is giving you a hard time about continuous glucose monitoring. Our guests this week are Bonnie Roswig, an attorney with a small...

info_outline
In the News... Hurricane aid, Medtronic recall, Mounjaro supply update, stem cell T1D success... and more! show art In the News... Hurricane aid, Medtronic recall, Mounjaro supply update, stem cell T1D success... and more!

Diabetes Connections | Type 1 Diabetes

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Hurricane aid for people with diabetes, Medtronic safety warning, stem cell updates for type 1, new study about teens and young adults with type 1, and Ryan Reed returns to racing. Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about   from extreme temperatures Learn more about  Drive  The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:...

info_outline
Mental Health and T1D –  Support & Advice from a Passionate Endo show art Mental Health and T1D – Support & Advice from a Passionate Endo

Diabetes Connections | Type 1 Diabetes

We know the importance of mental health support during a type 1 diagnosis, so why isn’t there much of any? We know the answers – time, money, patient and caregiver bandwidth, but can’t we do something here? I’m talking to an endo who feels passionately that we can, and his team is trying their best in our difficult system to make a difference. He’s got actionable advice for you, even if your health care team doesn’t provide mental health resources. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please...

info_outline
Testing for T1D has changed - what you (and your doctor) need to know about screening show art Testing for T1D has changed - what you (and your doctor) need to know about screening

Diabetes Connections | Type 1 Diabetes

We’ve been hearing a lot more about screening for type 1 diabetes – I saw my first mainstream commercial for it last week – but what does that mean? If you have type 1 or you have a child with T1D, are you thinking about screening other family members? Should you? Over the summer new guidelines were announced for health care providers – including mental health guidelines. There’s a lot to unpack here.. my guest is the director of community screening and clinical trials education with BT1D. My guest this week is Anastasia Albanese-O'Neill, the director of community screening and...

info_outline
In the News... Insulin price lawsuit, new CGM approved, diabetes camp scholarships... and more! show art In the News... Insulin price lawsuit, new CGM approved, diabetes camp scholarships... and more!

Diabetes Connections | Type 1 Diabetes

It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The FTC sues PBMs over insulin pricing, a new CGM is approved in Europe, more news about GLP-1s but some research says it may not work as well for one population, diabetes camps are invited to apply for grants, and more! Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about   from extreme temperatures Learn more about  Drive  The best way to keep up with Stacey and the show is by...

info_outline
How How "Accidental Demons" author Clare Edge keeps diabetes real, even in a fantasy novel

Diabetes Connections | Type 1 Diabetes

Clare Edge says “Diabetes is the least interesting thing about me, I don't actually like talking about it.” But she also wrote a fantastic new book all about – diabetic witch. The main character of "Accidental Demons" is a middle school aged witch with type 1 who can’t stop conjuring when she pricks her finger. We’ll talk about the book, Clare’s story of finding her way in the diabetes community, fighting the pursuit of perfection, and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn ...

info_outline
A new era of CGM? Dexcom’s Jake Leach on Stelo, G7 updates and more. show art A new era of CGM? Dexcom’s Jake Leach on Stelo, G7 updates and more.

Diabetes Connections | Type 1 Diabetes

For the first time, you can buy a continuous glucose monitor over the counter, no prescription needed. This summer we went from no CGMs available this way, to now having two. This week we’re talking about the Dexcom Stelo with the company’s COO Jake Leach. We’ll talk about Stelo and get an update on G7 features including Dexcom’s plans to address concerns over Geofencing, and issues that can potentially arise if you travel outside your home country. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please...

info_outline
 
More Episodes

It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A weekly basal plus semaglutide is in the works, but not for the US right now, Tandem updates it's app recall, liver targeted insulin study, a weird walking story, and Lance Bass educates about LADA. 

Find out more about Moms' Night Out 

Please visit our Sponsors & Partners - they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

Omnipod - Simplify Life

Learn about Dexcom 

Edgepark Medical Supplies

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here's where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 

Reach out with questions or comments: [email protected]

Episode transcription with links:

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.

XX

Novo Nordisk moves ahead with a new combination: once-weekly insulin icodec and semaglutide. Called IcoSema, Novo plans to submit for approval in Europe, Canada, Japan and Australia but NOT the US.

As we told you earlier this summer, icodec – once weeky basal insulin – was not approved by the US FDA.

Semaglutide is the molecule underpinning Novo’s immensely popular GLP-1 drugs Ozempic and Wegovy. Icodec has been approved as Awiqli in places like Europe, Canada, Japan and Australia but was snubbed by the FDA last month.

The FDA has left the door open for another application, but Novo says they don’t expect to iron it out this year.

In studies, the combination worked well to lower A1C for people with type 2 and they lost weight. They also had fewer lows.

https://www.fiercepharma.com/pharma/corrected-after-icodec-rejection-novo-nordisk-wont-file-application-once-weekly-insulin-and

 

XX

An update from Tandm on their app recall. Back in March they notified users of the recall because of an issue that can cause rapid depletion of a user’s t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience even after an updated version of the app was released.

Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release.

Impacted customers in the U.S. with questions about this recall can contact the Tandem Diabetes Care Technical Support Team 24 hours a day, 7 days a week at [email protected] or (877) 801-6901.

https://www.businesswire.com/news/home/20240812040222/en/Tandem-Diabetes-Care-Provides-Update-on-March-2024-Nationwide-Recall-of-tconnect-Mobile-App-for-iOS-Devices

XX

If you are an adult who has type 1 diabetes, you may be eligible to participate in a trial examining the impact of an investigational liver-targeted insulin on blood glucose control, A1C, and nighttime lows.

This study is researching whether administering a liver-targeting insulin called HDV-L insulin (Hepatocyte-directed Vesicles-insulin lispro), will improve glycemic control.

HDV-L insulin is designed to act on the liver to enhance glucose storage and decrease the frequency of severe hypoglycemia in individuals requiring insulin. It is not currently approved for use.

For this trial, researchers are recruiting roughly 230 adults with type 1 diabetes aged 18-79 who are on multiple daily injections (MDI).

This study is recruiting in California, Colorado, Florida, Georgia, Illinois, Indiana, New York, North Carolina, Ohio, and Texas. To enroll or learn more about this study, contact Todd Hobbs, MD at Diasome Pharmaceuticals at [email protected] or call 216-780-9324.

Clinical Trials Identifier: NCT06238778

https://diatribe.org/diabetes-research/new-study-tests-liver-targeted-insulin-type-1-diabetes

XX

Sanofi is investing heavily to boost insulin production. They opened a new facility in Germany for the basal insulin Lantus and they announced they will invest over one billion dollars to expand production capacity in France.

Sanofi’s considerable investment in insulin production is especially important given that other insulin companies appear to be focusing their efforts on production of GLP-1 medications like Mounjaro and Ozempic, rather than insulin. This has left some patients worried that Novo Nordisk and Lilly will leave them behind to pursue more lucrative products for weight loss, especially after Novo Nordisk decided to discontinue the basal insulin Levemir.

https://diatribe.org/diabetes-medications/sanofi-build-new-state-art-insulin-plant

 

XX

Hoping to talk to Abbott and Medtronic soon about their partnership announced earlier this month. The companies announced that Abbot will create an integrated continuous glucose monitor that works only with Medtronic’s diabetes technology and be sold exclusively by Medtronic.

Along with announcing the partnership, Medtronic said Wednesday it received FDA approval for its Simplera CGM, which does not require fingersticks or overtape, unlike the company’s previous sensors.

The Simplera Sync sensor, which is designed to work with Medtronic’s automated insulin delivery algorithm, is under FDA review separately.

https://www.medtechdive.com/news/abbott-medtronic-partnership-automated-insulin-delivery/723600/

XX

Researchers have developed a novel computer algorithm that can predict various diseases like diabetes or stroke, just by analysing the colour of the human tongue with 98 per cent accuracy.

The imaging system developed by Middle Technical University (MTU) and the University of South Australia (UniSA) in Australia can diagnose conditions such as diabetes, stroke, anaemia, asthma, liver and gallbladder issues, Covid-19, and other vascular and gastrointestinal diseases.

"The colour, shape, and thickness of the tongue can reveal a litany of health conditions," said Ali Al-Naji, adjunct Associate Professor at MTU and UniSA.

The paper published in Technologies describes how the system analyses tongue colour to provide real-time diagnoses, demonstrating that AI can advance medical practices significantly.

The breakthrough was achieved through a series of experiments using 5,260 images to train machine-learning algorithms to detect tongue colour.

Researchers received 60 tongue images from two teaching hospitals in the Middle East, representing patients with diverse health conditions. The AI model matched tongue colour with the correct disease in nearly all cases.

https://www.ndtv.com/world-news/new-algorithm-analyses-tongue-to-predict-diabetes-stroke-with-98-accuracy-6327124

XX

Big roundup article from the UK Guardian all about 6 projects all around smart insulin. Not a lot new here, but it caused a lot of chatter. I’ll link it up – good summary of all of the research happening in the space right now. Glucose-responsive insulin is the idea that you could give one injection and the insulin would respond to the rise and fall of glucose levels without further action by the person.

 

https://www.theguardian.com/society/article/2024/aug/11/scientists-hail-smart-insulin-responds-changing-blood-sugar-levels-real-time-diabetes

XX

Edgepark Commercial

XX

Lance Bass (like glass) continues to keep the public posted on his recent LADA diagnosis. The boy band singer showing his IG audience more about what’s also called diabetes 1.5 and explaining how he was first diagnosed with type 2.

XX

Ok, brace yourself – I promise this is a real story. The Fart Walk is actually good for you. Ok.. stay with me. This is really just a great silly reframing of something we all know, and I couldn’t resist putting it in here. A wellness influencer put this out – you may have seen it – claiming the after dinner stroll can limit your risk of type 2 diabetes. A lot of studies confirm that – along with it having benefits if you already have diabetes. The flatulence part – or a release of gastric pressure – is also a known benefit of moving more after meals. So it’s funny, farts are always funny, but if it gets more people to walk after they eat I’m all for it.

 

https://people.com/fart-walk-benefits-what-is-it-type-2-diabetes-8694630#:~:text=Wellness%20influencer%20Mairlyn%20Smith%20has,of%20day%20you%20do%20it

XX

Join us again soon!